Study guide
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy
Key Takeaways Explain This Topic AI
Pediatric cardiopulmonary arrest is predominantly hypoxic-asphyxial in origin; progressive bradycardia is the cardinal herald of impending respiratory arrest and cardiovascular collapse, mandating immediate oxygenation, ventilation, and chest compressions if heart rate is <60 beats/min with poor perfusion.
Length-based resuscitation tapes (e.g., Broselow tape) establish standardized weight-band cohorts to eliminate dosing calculation errors; hydrophilic resuscitation medications should be dosed on length-predicted ideal body weight to prevent toxicity.
PALS cardiac arrest pharmacotherapy requires Epinephrine 0.01 mg/kg IV/IO (0.1 mL/kg of the 0.1 mg/mL concentration) every 3 to 5 minutes, with Amiodarone (5 mg/kg IV/IO bolus, up to 15 mg/kg total) or Lidocaine (1 mg/kg IV/IO bolus, maintenance 20-50 mcg/kg/min) for shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.
Pediatric status epilepticus requires strict timed intervention: Phase 1 emergent therapy delivers IV lorazepam (0.1 mg/kg, max 4 mg) or intranasal/intramuscular midazolam (0.2 mg/kg, max 10 mg); Phase 2 urgent control provides IV levetiracetam (60 mg/kg, max 4500 mg) or IV fosphenytoin (20 mg PE/kg, max 1500 mg PE).
The Rule of 50s governs pediatric hypoglycemia resuscitation: concentration (%) multiplied by volume (mL/kg) equals 50 (D10W 5 mL/kg in infants, D25W 2 mL/kg in children over about 2 years, D50W 1 mL/kg in adolescents); newborns usually receive D10W 2 mL/kg (200 mg/kg).
Last updated: October 2026
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around emergency medicine pharmacotherapy principles tested on clinical specialist certification examinations.
Pediatric Emergency Physiology & Airway-Centric Resuscitation
Pediatric cardiopulmonary arrest exhibits fundamental physiological differences from adult cardiac arrest. While sudden cardiac arrest in adults is overwhelmingly arrhythmogenic (primary ventricular fibrillation or pulseless ventricular tachycardia secondary to ischemic coronary artery disease), pediatric cardiac arrest is predominantly hypoxic-asphyxial in etiology. It represents the end-stage consequence of progressive respiratory failure (e.g., severe bronchiolitis, foreign body aspiration, status asthmaticus) or uncompensated shock (e.g., septic shock, severe dehydration).
Cardiovascular Dynamics & Rate Dependence
The immature pediatric myocardium is characterized by non-compliant ventricles, fewer contractile myofibrils, and incomplete sympathetic innervation. Consequently, the pediatric heart cannot substantially augment stroke volume in response to hypoperfusion. Cardiac output is almost entirely heart-rate dependent :
Cardiac Output = Heart Rate × Stroke Volume
In pediatric patients, tissue hypoxia and acidosis rapidly depress sinoatrial node automaticity and atrioventricular conduction. Therefore, progressive bradycardia is the primary clinical herald of impending respiratory arrest and cardiovascular collapse , rather than an isolated primary cardiac conduction pathology.
Important
According to Pediatric Advanced Life Support (PALS) guidelines, if a pediatric patient presents with a heart rate <60 beats/min with signs of poor systemic perfusion (e.g., altered mental status, weak central pulses, delayed capillary refill >2 seconds, mottled cool extremities) despite effective bag-valve-mask oxygenation and ventilation, immediate chest compressions must be initiated concurrently with pharmacotherapy .
Weight Estimation & Length-Based Tapes
Accurate weight estimation is essential to avoid fatal under- or overdosing in pediatric resuscitations. When the patient's exact weight is unknown, length-based resuscitation tapes (e.g., Broselow tape) correlate body length to predetermined weight cohorts (color zones ranging from pink [6-7 kg] to green [30-36 kg]).
Dosing in Obese Pediatric Patients : In obese children, length-based tapes estimate ideal body weight (IBW). Resuscitation medications that are highly water-soluble or distribute primarily into extracellular fluid (e.g., epinephrine, adenosine, succinylcholine, aminoglycosides) must be dosed on length-predicted ideal body weight to avoid life-threatening supratherapeutic peak concentrations. Lipophilic medications (e.g., fentanyl, midazolam) may require dosing based on adjusted or total body weight depending on volume of distribution.
- PALS Cardiac Arrest Resuscitation Algorithm PALS CARDIAC ARREST ALGORITHM
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Sudden Collapse / Pulseless Arrest: Initiate CPR (15:2 with 2 rescuers) │
- │ Attach Monitor / Defibrillator & Establish IV or IO Access │
- └──────────────────────────────────────┬──────────────────────────────────────┘
- ▼
- Check Cardiac Rhythm
- │
- ┌───────────────────────┴───────────────────────┐
- ▼ SHOCKABLE ▼ NON-SHOCKABLE
- [ VF / Pulseless VT ] [ Asystole / PEA ]
- │ │
- ┌──────────────┴──────────────┐ ┌──────────────┴──────────────┐
- │ • Defibrillate 2 J/kg │ │ • CPR immediately (2 min) │
- │ • CPR 2 min immediately │ │ • Epinephrine 0.01 mg/kg │
- │ • Defibrillate 4 J/kg │ │ IV/IO (0.1 mL/kg of │
- │ • Epinephrine 0.01 mg/kg │ │ 0.1 mg/mL) q3-5min │
- │ • Defibrillate ≥4 J/kg │ │ • Identify / treat 6 H's │
- │ • Amiodarone 5 mg/kg bolus │ │ and 5 T's │
- │ (or Lidocaine 1 mg/kg) │ └─────────────────────────────┘
- └─────────────────────────────┘
- Cardiac Arrest Pharmacotherapy
Epinephrine :
Mechanism : Alpha-1 mediated vasoconstriction increases systemic vascular resistance, elevating coronary and cerebral perfusion pressure during chest compressions; beta-1 adrenergic stimulation enhances inotropy and chronotropy.
IV/IO Dose : 0.01 mg/kg of the 0.1 mg/mL concentration (1:10,000 formulation), equivalent to 0.1 mL/kg (maximum single dose 1 mg / 10 mL). Administer every 3 to 5 minutes .
Endotracheal (ET) Dose : IV or IO access is strongly preferred because ET absorption is unreliable, and the 2025 adult guidelines dropped the ET route. If neither IV nor IO access can be obtained, older PALS teaching uses 0.1 mg/kg of the 1 mg/mL concentration (1:1,000 formulation), equivalent to 0.1 mL/kg (maximum 2.5 mg), followed by a 5 mL normal saline flush and 5 rapid positive pressure ventilations.
Amiodarone :
Indication : Shock-refractory ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT) after at least 2 to 3 defibrillation attempts.
Dose : 5 mg/kg IV/IO rapid bolus (maximum single dose 300 mg). May repeat twice up to a maximum cumulative dose of 15 mg/kg (or adult maximum 2.2 g over 24 hours).
Lidocaine :
Indication : Alternative to amiodarone for shock-refractory VF/pVT.
Dose : 1 mg/kg IV/IO initial bolus , followed by a continuous maintenance infusion of 20 to 50 mcg/kg/min .
Pediatric Bradycardia with Poor Perfusion
In children, bradycardia is defined clinically as a heart rate slower than normal for age (typically <60 bpm in infants and young children). When associated with cardiorespiratory compromise, it requires rapid pharmacotherapy:
Ventilation & Oxygenation : The initial and most critical intervention is establishing an open airway and delivering 100% oxygen via positive pressure ventilation.
Chest Compressions : If HR remains <60 bpm with poor perfusion despite 30 seconds of effective ventilation, start chest compressions immediately.
Epinephrine : First-line agent for persistent symptomatic hypoxic bradycardia. Dose: 0.01 mg/kg IV/IO (0.1 mL/kg of 0.1 mg/mL formulation) every 3 to 5 minutes.
Atropine :
Indications : Specifically indicated for bradycardia caused by increased vagal tone (e.g., post-intubation vagal surge, nasopharyngeal suctioning), primary atrioventricular (AV) block , or organophosphate toxicity.
Dose : 0.02 mg/kg IV/IO .
Critical Thresholds : Minimum single dose is 0.1 mg (to prevent paradoxical central vagal stimulation and worsening bradycardia caused by subtherapeutic doses); maximum single dose is 0.5 mg in a child and 1.0 mg in an adolescent .
Pediatric Tachycardias: Supraventricular Tachycardia (SVT)
Narrow-complex tachycardias must be differentiated into Sinus Tachycardia versus Supraventricular Tachycardia (SVT):
- Diagnostic Feature Sinus Tachycardia Supraventricular Tachycardia (SVT)
- Heart Rate Typically <220 bpm (infants); <180 bpm (children) >220 bpm (infants); >180 bpm (children)
- P Waves Present, normal axis, identifiable Absent or abnormal (retrograde/buried in T wave)
Heart Rate Variability Variable (fluctuates dynamically with fever/crying) Monotonous, fixed, no beat-to-beat variability
- Onset / Termination Gradual acceleration and deceleration Abrupt, paroxysmal initiation and termination
- Management of Pediatric SVT
Hemodynamically Stable :
Vagal Maneuvers : In infants and toddlers, apply an ice bag to the upper half of the face for 15 to 20 seconds, ensuring no airway obstruction or ocular compression. In older children, perform a modified Valsalva maneuver (blowing into a 10 mL syringe).
Adenosine Pharmacotherapy :
Mechanism : Slows conduction time through the AV node, interrupting AV nodal re-entry pathways.
Initial Dose : 0.1 mg/kg rapid IV/IO push (maximum initial dose 6 mg ).
Second Dose : If no conversion within 1 to 2 minutes, administer 0.2 mg/kg rapid IV/IO push (maximum second dose 12 mg ).
Administration Technique : Adenosine has an ultra-short half-life (<10 seconds). It must be administered via a proximal IV site (antecubital or central) using a two-syringe stopcock technique, followed immediately by a rapid flush of 5 to 10 mL normal saline .
Hemodynamically Unstable (Hypotension, altered mental status, signs of shock):
Perform immediate synchronized cardioversion at 0.5 to 1 J/kg .
If refractory, escalate subsequent cardioversion energy to 2 J/kg .
Pediatric Status Epilepticus: Timed Pharmacotherapy Pathways
Pediatric Status Epilepticus (SE) is defined as continuous seizure activity lasting >5 minutes or recurrent seizures without full return to baseline neurological status between episodes. Prolonged seizure activity results in excitotoxic NMDA receptor upregulation, GABA-A receptor internalization, blood-brain barrier disruption, and irreversible neuronal injury.
Phase 1: Emergent Initial Therapy (0 to 10 Minutes)
Intravenous Access Available :
Lorazepam : 0.1 mg/kg IV (maximum single dose 4 mg ), administered slowly over 2 minutes. May repeat once at 5 to 10 minutes if seizures persist.
No Intravenous Access (Prehospital / Rapid Bedside) :
Midazolam : 0.2 mg/kg intranasally (IN) or intramuscularly (IM) (maximum single dose 10 mg ). Intranasal delivery requires the concentrated 5 mg/mL injectable formulation divided equally between both nares using a mucosal atomization device (MAD).
Diazepam Rectal Gel : 0.2 to 0.5 mg/kg PR (maximum 20 mg) if midazolam is unavailable.
Phase 2: Urgent Control Therapy (10 to 30 Minutes)
If seizures continue despite adequate first-line benzodiazepine administration (established status epilepticus), non-sedating IV antiepileptic drugs (AEDs) must be initiated immediately. The landmark ESETT trial demonstrated equivalent efficacy (~45-50% seizure cessation at 60 minutes) among three primary agents:
Levetiracetam : 60 mg/kg IV (maximum single dose 4,500 mg ), infused over 10 to 15 minutes. Preferred in hepatic disease; low drug-interaction profile.
Fosphenytoin : 20 mg PE/kg IV (maximum single dose 1,500 mg PE ), infused at a rate not to exceed 150 mg PE/min (or 3 mg PE/kg/min). Water-soluble prodrug that avoids the propylene glycol vehicle toxicities of phenytoin (phlebitis, purple glove syndrome, severe hypotension).
Valproate Sodium : 40 mg/kg IV (maximum single dose 3,000 mg ), infused over 10 minutes. Strictly contraindicated in children with known or suspected mitochondrial disorders (e.g., POLG mutations) or urea cycle disorders due to fatal hepatotoxicity and hyperammonemic encephalopathy.
- Pediatric Fluid Resuscitation & The Hypoglycemia "Rule of 50s"
- Fluid Resuscitation in Pediatric Septic Shock
Initial Volume : Administer 10 to 20 mL/kg of balanced crystalloid (Lactated Ringer's or Plasma-Lyte) as an intravenous push or rapid pressure bag infusion over 10 to 20 minutes.
Reassessment & Fluid Overload : Following each bolus, rigorously examine the patient for signs of fluid overload: hepatomegaly , new or worsening pulmonary crackles/rales , increased work of breathing, or gallop rhythm. If signs of fluid overload appear, stop fluid boluses immediately and initiate vasoactive infusions (epinephrine for cold shock; norepinephrine for warm vasodilatory shock).
Acute Hypoglycemia Resuscitation: The "Rule of 50s"
Pediatric patients have limited hepatic glycogen stores and elevated basal metabolic rates, predisposing them to profound neuroglycopenia. Hypoglycemia thresholds: neonates <45 mg/dL; infants and children <60 mg/dL.
To prevent osmolar injury, fluid shifts, and chemical phlebitis, dextrose concentrations are selected based on age using the Rule of 50s :
Dextrose Concentration (%) × Volume (mL/kg) = 50
- Patient Population Dextrose Concentration Weight-Based Dose Calculation Validation
- Infants (about 1 month to 2 years) D10W (10% Dextrose) 5 mL/kg IV 10% × 5 mL/kg = 50
- Newborns D10W 2 mL/kg IV (200 mg/kg), then a dextrose infusion Smaller bolus avoids rebound hyperinsulinemia
- Children (>2 years to adolescence) D25W (25% Dextrose) 2 mL/kg IV 25% × 2 mL/kg = 50
- Adolescents / Adult Size D50W (50% Dextrose) 1 mL/kg IV (max 25-50 g) 50% × 1 mL/kg = 50
Caution
Hypertonic dextrose (D25W or D50W) should never be administered to neonates or young infants. Hyperosmolar solutions in this vulnerable population provoke sudden plasma hyperosmolality, osmotic cellular dehydration, and catastrophic intraventricular hemorrhage.